Mood Disorders: Diagnosis, Management and Future Opportunities
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Mental Health".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 75
Special Issue Editor
Interests: behavioral psychology; cognitive neuroscience; mental illness; cognition disorders; sex differences
Special Issue Information
Dear Colleagues,
Over the last decade, the World Health Organization has reported a 13% increase in mental health problems, primarily mood disorders in adolescents and young adults, increasing suicidal thoughts and other suicide-related outcomes. In parallel, there have been important advances in the pharmacology, psychotherapy and neurobiology of mood disorders, improving their diagnosis and treatment.
New perspectives take into account sex differences, comorbidity, risk and protective factors, the transdiagnostic approach, the effects of digital media, and even genomic and epigenetic changes.
This Special Issue aims to expand the information on advances in the diagnosis and treatment of mood disorders, with a special interest in the most recent perspectives.
The topics of interest for publication include, among others, advances in diagnosis and clinical tools, as well as the treatment of these disorders from an integrative, biopsychosocial perspective.
Dr. Natalia Lagunas
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mood disorders
- depression
- anxiety
- stress, trauma
- suicide
- mental health diagnosis and treatment
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: War Exposure and PTSD in Multiple Sclerosis Patients in Jor-dan: Correlates and Prevalence During the Gaza Conflict
Authors: Lorca Alzoubi; Esam Qnais; Hanan Abu-Shaikh; Mohammad Mansour; Suha Al-Habahbeh; Feras Weshah; Wail Ennab; Abdelrahim Alqudah; Badriyah S. Alotaibi; Alaa A. A. Aljabali; and Omar Gammoh
Affiliation: Department of Pharmaceutics and Pharmaceutical Technology; Faculty of Pharmacy, Yarmouk Uni-versity Irbid 21163, PO BOX 566, Jordan
Abstract: The ongoing war on Gaza has a psychological impact on the Jordanian knit. People with Multi-ple Sclerosis (PwMS) are fragile to mental distress, especially in times of crisis. This study sought to unravel the prevalence and correlates of the self-reported Post Traumatic Stress Disorder (PTSD) symptoms in a group of people with MS in Jordan during the Gaza war outbreak. This cross-sectional study that used predefined inclusion criteria employed a translated and validated scale to measure PTSD symptoms. Data were analyzed from 171 patients, 125 (73.1%) were fe-males, 90 (52.6%) were on fingolimod, 34 (19.9%) were on dimethyl fumarate, 47 (27.5%) were on interferons, in addition, 98 (57.3%) were on therapy for less than five years, and 30 (17.5%) re-ported having a relapse during the past 6 months. PTSD severe symptoms were screened in 100 (58.1%). Unemployed PwMS were at a higher risk (OR=2.14, 95% CI= 1.13-4.07, p=0.02) for severe PTSD symptoms, conversely, patients receiving dimethyl fumarate were reported lower odds (OR=0.43, 95%CI=0.19-0.94, p =0.02) for severe PTSD symptoms. In conclusion, this study reports a very high rate of PTSD in patients with MS, a comprehensive multidisciplinary approach is required to improve the mental well-being of this fragile population.
